 LEXINGTON, Mass., Oct. 01, 2021 GLOBE NEWSWIRE -- Agenus Inc. NASDAQ: AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced acceptance of its abstract describing updated Phase 1 clinical trial results for AGEN1181 Fc-enhanced anti-CTLA-4 alone and in combination with balstilimab anti-PD-1 at the Society for Immunotherapy of Cancer SITC 36th Annual Meeting, to be held November 10-14, 2021. 